| Literature DB >> 35096766 |
Abstract
Extensive efforts have been made in the last decades to simplify the holistic sample preparation process. The idea of maximizing the extraction efficiency along with the reduction of extraction time, minimization/elimination of hazardous solvents, and miniaturization of the extraction device, eliminating sample pre- and posttreatment steps and reducing the sample volume requirement is always the goal for an analyst as it ensures the method's congruency with the green analytical chemistry (GAC) principles and steps toward sustainability. In this context, the microextraction techniques such as solid-phase microextraction (SPME), stir bar sorptive extraction (SBSE), microextraction by packed sorbent (MEPS), fabric phase sorptive extraction (FPSE), in-tube extraction dynamic headspace (ITEX-DHS), and PAL SPME Arrow are being very active areas of research. To help transition into wider applications, the new solventless microextraction techniques have to be commercialized, automated, and validated, and their operating principles to be anchored to theory. In this work, the benefits and drawbacks of the advanced microextraction techniques will be discussed and compared, together with their applicability to the analysis of pharmaceuticals in different matrices.Entities:
Keywords: SPME; green analysis; microextraction; pharmaceuticals; solventless extraction
Year: 2022 PMID: 35096766 PMCID: PMC8792605 DOI: 10.3389/fchem.2021.785830
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Process of extraction of analytes using direct immersion and headspace SPME that further coupled to chromatographic instrument (GC-MS or LC-MS or CE).
FIGURE 2(A) Immersion–agglutination coating procedure to obtain IL- or PIL-coated SPME fibers. (B) MIP fabrication and coating of SPME fibers.
FIGURE 3(A) General procedure applied in MEPS extraction. (B) General procedure applied in FPSE. (C) General procedure applied in SBSE. (D) General procedure applied in magnetic nanoparticle extraction.
FIGURE 4Difference between classical SPME fiber and the PAL SPME arrow.
Advantages and limitations of some green solid phase-based extraction techniques.
| Microextraction technique | Advantages | Disadvantages |
|---|---|---|
| Solid phase microextraction (SPME) | No need for solvents | Robustness of fiber coatings |
| Rapid, simple and sensitive | Stationary phase of limited range | |
| Used for polar and non-polar analytes | In-between batch variations | |
| Applicable with wide range of matrices | ||
| Compatible with different separation and detection systems | ||
| Suitable for headspace and immersion modes | ||
| In-tube extraction dynamic headspace (ITEX-DHS) | High sorption capacity | Stationary phase of limited range |
| Many available commercial sorbent materials | ||
| External heater unit allows independent desorption | ||
| Solid-phase dynamic extraction (SPDE) | More sensitive than SPME | Carryover; analytes might remain on the needle inner wall |
| Robust | ||
| Shorter extraction time than SPME | Stationary phase of limited range | |
| Smaller sample size than SPME | ||
| More complicated analytical process | ||
| Microextraction in a packed sorbent (MEPS) | Short procedure time | Clogging of the barrel insert and needle |
| Applicable with wide range of matrices | Not very suitable for processing large volume samples | |
| More simple analytical procedure | Limited range of sorbents available | |
| Reuse sorbents many time | ||
| Economical | ||
| Fabric phase sorptive extraction procedures (FPSE) | No special equipment or set-up is needed, flexible technique | Longer extraction time |
| Stable even in harsh chemical environment (pH 1–13) | ||
| High primary contact surface area (efficient extraction) | ||
| Low solvent required for quantitative desorption | ||
| Low risk of cross-contamination | ||
| Stir bar sorptive extraction (SBSE) | Lower detection limit than SPME | High matrix effects |
| Compatible with different separation and detection systems | Limited number of commercially available coatings | |
| High thermal and chemical stability of stir-bar coatings | Requires high control of extraction conditions | |
| Suitable for headspace and immersion modes | High enrichment factor only for non-polar analytes | |
| Higher enrichment factor than SPME | Possibility of bleeding at even relatively during thermal desorption | |
| Magnetic nanoparticle extraction | Good cleanup of matrix and the interference compounds | Particle agglomeration that leads to low extraction efficiency |
| No loss of analytes | Oxidation of magnetic cores | |
| PAL SPME Arrow | Higher extraction capacity than SPME | Limited mechanical stability |
| High mechanical robustness | Small phase volumes of the fibers | |
| Trace-level sensitivity | ||
| Can be fully automated |
Applications of the microextraction techniques discussed in this review for determination of pharmaceuticals in different matrices.
| Application | Analyte | Extraction method | Matrix | LOD/LOQ (ng/ml) | Recovery | Analysis method | References |
|---|---|---|---|---|---|---|---|
| Environmental | Antioxidants, UV filters, and fragrances | SPME(PDMS) | Tap water | 5–8,500 | nr | GC-MS |
|
| Estriol, estradiol, ethynylestradiol, estrone, progesterone, medroxyprogesterone, levonorgestrel, and norethindrone | SBSE | Water (tap water and raw | 0.5 × 10–3–1.0 | 556–96% | MS |
| |
| Wastewater | |||||||
| Triclosan, triclocarban, and their four related transformation products | SPME | Water | 0.06–0.21 | 81.54–102.32% | HPLC-DAD |
| |
| 0.12–0.73 | |||||||
| Triclosan and bisphenol-A | SPME (CW/TPR) | Tap, river and | 1 | 71–111 | HPLC-DAD |
| |
| Chlorophenols and mefenamic acid | Wastewater | 2–9 | |||||
| Gemfibrozil | 3 | ||||||
| Steroids | SPME (PDMS/DVB) | Local source water | 30–2,000 | 84.9–103% | GC-MS/MS |
| |
| Mesterolone | |||||||
| Methandriol | |||||||
| Estrone | |||||||
| Estradiol | |||||||
| Androstenedione | |||||||
| Eticholan-3–17-one | |||||||
| DES | |||||||
| Prasterone | |||||||
| Sulfonamides, sulfacetamide, sulfadiazine, sulfathiazole, sulfamethazine, sulfamethoxypyridazine, and sulfamethoxazole | MEPS(C8) | Wastewater | 5–200 | 88–109% | HPLC-DAD |
| |
| Flufenamic acid and mefenamic acid | SPME | Water | 6 × 10−5–1.24 × 10−3 | 85.1–110.8% | GC-MS |
| |
| Flurbiprofen | 2.2 × 10−4–4.13 × 10−3 | ||||||
| Clofibrate | |||||||
| Ketoprofen | |||||||
| Naproxen | |||||||
| Tolfenamic acid | |||||||
| Gemfibrozil | |||||||
| Estriol, 17β-estradiol, testosterone, ethinylestradiol, estrone, progesterone, and mestranol | SPME-fiber | Water | nr | 75.6–116% | HPLC |
| |
| Androgens and progestogens | FSPE (sol-gel PTHF) | Water, urine | 1.7 × 10−3–0.264 (water samples) | 83.8–103.9% water | UHPLC–MS/MS |
| |
| Norethisterone | 8.9 × 10−3–0.132 (urine samples) | 81.9–120% urine | |||||
| Norgestrel | |||||||
| Megestrol acetate | |||||||
| Progesterone | |||||||
| Boldenone | |||||||
| Nandrolone | |||||||
| Testosterone | |||||||
| DHEA | |||||||
| Androsterone | |||||||
| Androstenedione | |||||||
| Penicillins (penicillin G, penicillin V, oxacillin, cloxacillin, dicloxacillin, and nafcillin) | SPME (Al-MOF) | River water | 0.06–0.26 | 80.8–90.9% in water | LC–MS or LC–UV |
| |
| 81.1–100.7% in milk | |||||||
| Abacavir | SPME-fiber | Surface waters and wastewater | 0.010–0.013 | 88–99% | LC-MS |
| |
| 0.033 | |||||||
| Chlorophenols and eleven estrogenic compounds | SPME | Surface water | 8.8 × 10−3–42.9 × 10−3 | 69–108% | GC-MS |
| |
| β-Estradiol | SBSE | Water | nr | 71.4–83.2% |
| ||
| 3-(4-metylbenzylidene)camphor | |||||||
| Carbamazepine | |||||||
| Ibuprofen | |||||||
| 2,4-dihidroxybenzophenone | |||||||
| Triclosan | SPME-Fiber (PDMS) | Seawater | 0.111, 0.177, 0.088 | nr | LC-MS/MS |
| |
| Bisphenol A | |||||||
| 17α-Ethynylestradiol | |||||||
| 4-Chloro-1-naphthol | SBSE | Wastewater, pool water | 0.034 | 87.4–141.3% | HPLC |
| |
| 0.400 | |||||||
| Biological (fluids and tissues) | NSAIDs | MEPS (C18) | Plasma, urine | 30–100 | nr | HPLC-PDA |
|
| Furprofen, indoprofen, ketoprofen, fenbufen, flurbiprofen, indomethacin, and ibuprofen | |||||||
| Selected estrogens | FSPE (sol-gel PTHF) | Urine | 0.036 | 88.7–98.0% | HPLC-FLD |
| |
| α-17-ethynylestradiol | 0.020 | ||||||
| β-Estradiol | 0.042 | ||||||
| α-Bisphenol A | |||||||
| Ciprofloxacin and levofloxacin, two fluoroquinolones | MEPS (C18) | Sputum | 17–50 | >80% | HPLC-PDA |
| |
| Cocaine, amphetamines, natural and synthetic opioids, and hallucinogens (AMP, MAMP, MDA, MDMA, and MDEA) | MEPS | Oral fluid | 1, 1, 1, 0.5 & 0.5 | >60% | LC-MS/MS |
| |
| Estriol, 17β-estradiol, testosterone, ethinylestradiol, estrone, progesterone, and mestranol | SPME-fiber | Urine | nr | 75.6–116% | HPLC |
| |
| Benzodiazepines | FSPE (sol-gel PEG) | Blood serum | 30 | nr | HPLC |
| |
| 10 | |||||||
| Abacavir | SPME-fiber | Urine | 43.9 × 10−3 | 88–99% | LC-MS |
| |
| 12 azole drugs (bifonazole, butoconazole, clotrimazole, econazole, itraconazole, ketoconazole, miconazole, posaconazole, ravuconazole, terconazole, tioconazole, and voriconazole) | MEPS (C18) | Plasma, urine | 0.23 and 0.37 | 88.5–99.2% | HPLC-DAD |
| |
| Trans,trans-muconic acid | MIP-MEPS | Urine | 50 | 89.8–91.6% | HPLC-UV |
| |
| 15 | |||||||
| Statins | MEPS (C18) | Plasma | 10–20 | nr | UHPLC-MS/MS |
| |
| Drugs of abuse | MEPS C8/SCX | Plasma | 5–10 | 80–104% | UPLC |
| |
| Morphine | |||||||
| Methylone | |||||||
| 6-AM | |||||||
| Mephedrone | |||||||
| BEG | |||||||
| Cocaine | |||||||
| MDPV | |||||||
| Cocaethylene | |||||||
| EDDP | |||||||
| Methadone | |||||||
| Voriconazole | SPME-MS | Human plasma | 3–6 | nr | Coated blade spray-MS |
| |
| Ciprofloxacin | FSPE (sol-gel Carbowax® 20 M) | Whole blood Plasma | 250 (10) | nr | HPLC-PDA |
| |
| Sulfasalazine | Urine | 110 (30) | |||||
| Cortisone | 100 (30) | ||||||
| Cyclosporine | SPME-MS | Whole blood | 3.0 | nr | Coated blade spray-MS/MS |
| |
| Tacrolimus | Whole blood | 0.3 | |||||
| Sirolimus | Whole blood | 1.0 | |||||
| Everolimus | Whole blood | 0.3 | |||||
| losartan and valsartan | SBSE | Human plasma | 7.0 | 98–117% | LC-MS |
| |
| 27.0 | |||||||
| Methylphenidate | SPME | Human heparin plasma | nr | nr | TD-ESI/MS |
| |
| Doxorubicin | SPME | Lung tissue | 103.2% | LC-MS/MS |
| ||
| Antibiotics and their metabolites (amoxicillin, cefotaxime, ciprofloxacin, clindamycin, metronidazole, amoxycilloic acid, 4-hydroxyphenyl glycyl amoxicillin, desacetyl cefotaxime, 3-desacetyl cefotaxime lactone, ciprofloxacin N-oxide, N-demethyl clindamycin, clindamycin sulfoxide, and hydroxy metronidazole | SPME-C18 fiber | Human whole blood and tissue samples | 28–45 | 89.29–98.39% | HPLC-QqQ-MS |
| |
| 85–135 | |||||||
| NSAIDs (ibuprofen, diclofenac, naproxen, and nalidixic acid) | SPME- Fe3O4/Cu3(BTC)2 MOF | Human urine, serum, plasma, and tablets | 0.03–0.05 | 94.0–102.0%. | HPLC |
| |
| 0.12–0.18 | |||||||
| Methamphetamine | SPME | Hair | 0.067 | 90.2–95.8% | LC-MS |
| |
| Amphetamine | 0.067 | ||||||
| Ketamine | 0.067 | ||||||
| Norketamine | 0.067 | ||||||
| Perphenazine, chlorpromazine, chlorprothixene, promethazine, and trifluoperazine | Hollow fiber SPME | Human whole blood and urine | 0.025, 0.0125, 0.025, 0.025 and 0.0125 | 46.4–96.6% (blood) | UPLC-MS/MS |
| |
| 65.2–101.9% (urine) | |||||||
| Alprazolam and amitriptyline | DI-SPME | Human blood and bone marrow | 1.87–10.45 | nr | LC-TOFMS |
| |
| Bromazepam and carbamazepine, citalopram | 5.60–31.35 | ||||||
| Clonazepam,clorazepate, desipramine, and diazepam | |||||||
| Estazolam, flunitrazepam, and fluoxetine | |||||||
| Imipramine, lorazepam, lormetazepam, midazolam, nitrazepam, nordazepam, and nortriptyline | |||||||
| Paroxetine, prazepam, and temazepam | |||||||
| Tetrazepam, venlafaxine, and zolpidem | |||||||
| 4-chloro-1-naphthol | SBSE | Human urine | 0.034 | 87.4–141.3% | HPLC |
| |
| 0.400 | |||||||
| Tranexamic acid | SPME-Thin film | Human plasma and urine | 10000–25000 | nr | LC-MS/MS |
| |
| Others (food, animal tissue, | Melatonin and other antioxidants | MEPS (C18) | Foodstuff | 0.02 | nr | HPLC-FLD |
|
| Carvedilol enantiomers | SBSE | Pharmaceutical dosage forms | 8 (R) and 11 (S) | 98–103% | HPLC |
| |
| 25 (R) and 50 (S) | |||||||
| Clenbuterol | SPME | Pork | 3.6 × 10−6 | 97.4–105.7%. | GC/MS |
| |
| Salicylic, 3-methyl salicylic, 4-methyl salicylic, acetylsalicylic, and benzoic acids | SPME | Fruits and vegetables | 2–28 | 78.0 ± 1.3% | HPLC |
| |
| 7–95 | |||||||
| Neurotransmitters | SPME | Macaque brain | 25–20,000 | 80–100% | LC-MS/MS |
| |
| 98 pharmaceutical analytes | SPME | Bovine tissue | (0.25–3X, where X corresponds to the MRL for each target analyte) | nr | SPME-DART-MS/MS |
|
nr: not reported.